American Cancer Society

Ultimate Medical Academy Extends “Ripple Effect of Care” Through Community Partnership and Service

Retrieved on: 
星期三, 五月 8, 2024
Education, Saint Andrew's Society, The Salvation Army, Stephanie, Woman, Breast cancer, Teaching, Hillsborough County Public Schools, Health, American Legion, Catholic school, American Cancer Society, Partnership, UMA, AHA, Female, Friends, ACS, Humane society, Ultimate Medical Academy, Patient, Ripple effect, Outreach, Medical billing, Student, American Heart Association, Organization, NAACP, Nursing

“At UMA, it starts with care for our team members who then extend care to our learners.

Key Points: 
  • “At UMA, it starts with care for our team members who then extend care to our learners.
  • As graduates, those learners pass care along to patients through their work with our healthcare employers nationwide.”
    The Ripple Effect of Care also extends into UMA’s communities through philanthropy, partnership and volunteerism, which is a cornerstone of UMA's community engagement.
  • For UMA, the ripple effect of care isn't just a philosophy—it's a lived reality, creating waves of positive change that resonate far and wide.
  • To learn more about Ultimate Medical Academy's community initiatives and view the full report, visit: Community Outreach | Giving Back | Ultimate Medical Academy

RadNet’s Lenox Hill Radiology to Host Mother’s Day Mammogram Screening Parties in New York City

Retrieved on: 
星期二, 五月 7, 2024
Breast cancer, Cancer, Sheryl Swoopes, New Yorker, Woman, Health, Heart, American Cancer Society, Lenox Hill, Female, Intelligence, Knowledge, Disease, White, WNBA, RadNet, Death, Medical imaging

In collaboration with Lenox Hill Radiology, RadNet will host Mother’s Day MammoGlam parties on Saturday, May 18, in New York City.

Key Points: 
  • In collaboration with Lenox Hill Radiology, RadNet will host Mother’s Day MammoGlam parties on Saturday, May 18, in New York City.
  • On a day that celebrates positive role models, the objective is to empower women to prioritize their health and well-being.
  • Who: WNBA Icon Sheryl Swoopes, New York State elected officials, breast specialists from Lenox Hill Radiology, and community leaders
    WNBA icon Sheryl Swoopes, a RadNet spokesperson and advocate for breast health, will emphasize the importance of convenient access to essential cancer screening services.
  • The three-time Olympic gold medalist and WNBA Most Valuable Player will be joined by select New York government officials at these Lenox Hill centers.

FDA Approves ColoSense™ – Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test

Retrieved on: 
星期一, 五月 6, 2024
FDA, Other Health, Practice Management, Surgery, Managed Care, Oncology, Women, Medical Devices, Hospitals, Men, Biotechnology, Science, Consumer, Research, Health, Medical Supplies, Cancer, Food, Large intestine, Colorectal cancer, Methylation, Death, American Cancer Society, CRC, RNA, LH, Disease, Incidence, Patient, Colonoscopy, Biomarker, Ageing, Vaccine

Geneoscopy, Inc. , a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense.

Key Points: 
  • Geneoscopy, Inc. , a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense.
  • ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average risk for developing CRC.
  • Designated as a Breakthrough Device by the FDA, ColoSense is the first noninvasive colorectal cancer screening test to provide a dynamic view of disease activity by using RNA biomarkers.
  • Colorectal cancer is the second deadliest cancer in the United States.

MemorialCare Cancer Institute Revolutionizes Prostate Cancer Treatment: Hot Water Potential Solution to Prostate Cancer

Retrieved on: 
星期二, 五月 7, 2024
Radiation, Cancer, Prostate cancer, Urinary incontinence, Surgeon, American Cancer Society, Urology, Research, Water, Oncology, Erectile dysfunction, Disease, Nursing, Patient, Social, Quality of life, Medical imaging

LAGUNA HILLS, Calif., May 7, 2024 /PRNewswire/ -- MemorialCare Cancer Institute at Saddleback Medical Center is the only location in Orange County – and one of only two in California – to offer a new, innovative way to treat prostate cancer patients with water vapor. This study, VAPOR 2, utilizes a minimally invasive and nonsurgical procedure that employs water vapor to target and destroy the walls of the cancer cells while minimizing damage to the surrounding healthy prostate tissue.

Key Points: 
  • A clinical trial tests if hot water vapor can attack cancer cells, in new non-surgical approach to prostate cancer treatment
    LAGUNA HILLS, Calif., May 7, 2024 /PRNewswire/ -- MemorialCare Cancer Institute at Saddleback Medical Center is the only location in Orange County – and one of only two in California – to offer a new, innovative way to treat prostate cancer patients with water vapor.
  • As the second most common cancer in U.S. men, the American Cancer Society estimates one in eight American men will be diagnosed with prostate cancer during their lifetime.
  • Prostate cancer is a serious disease often treated with therapies that cause complications, such as urinary incontinence and erectile dysfunction.
  • "We believe clinical trials are the front line in winning the battle against cancer," says Elizabeth "Liz" Acord, vice president, clinical integration, MemorialCare Cancer Institute.

To Drive a Deeper Understanding of Cancer Disparities, American Cancer Society Launches Largest U.S. Population Study of Black Women

Retrieved on: 
星期二, 五月 7, 2024
Mortality, Cancer, Health equity, United, Lung cancer, Risk, Woman, Health, Survival, Estate (law), American Cancer Society, Research, Area studies, Obesity, Female, ACS, Science, Diagnosis, Meat, Social justice, Tobacco, Birth control

ATLANTA, May 7, 2024 /PRNewswire/ -- Today, the American Cancer Society (ACS) is proud to announce the launch of the VOICES of Black Women® study, the largest behavioral and environmental focused population study of cancer risk and outcomes in Black women in the United States.  Designed to better understand the multi-level drivers of cancer incidence, mortality and resilience within this demographic, the long-term study will gather valuable data from Black women between the ages of 25 and 55 from diverse backgrounds and income levels who have not been diagnosed with cancer. The organization aims to enroll over 100,000 Black women across 20 states and D.C. where, according the U.S. Census, more than 90 percent of Black women in the U.S. reside.

Key Points: 
  • The organization aims to enroll over 100,000 Black women across 20 states and D.C. where, according the U.S. Census , more than 90 percent of Black women in the U.S. reside.
  • "VOICES of Black Women® represents a crucial step towards achieving health equity in a population that is long overdue," said Patel, co-principal investigator of the study and senior vice president of population science at the American Cancer Society.
  • The American Cancer Society believes everyone should have a fair and just opportunity to prevent, find, treat and survive cancer.
  • For more information about the VOICES of Black Women® study and how to participate, please visit voices.cancer.org .

The 2024 Milken Institute Global Conference Opens May 5, Convening Global Leaders to Discuss Strategies Aimed at Shaping a Shared Future

Retrieved on: 
星期四, 五月 2, 2024
Environmental Health, Mental Health, Professional Services, Public Policy, Government, Foundation, Philanthropy, Health, Other Philanthropy, White House, Federal Government, Thought Leadership, State, Local, Communications, Environmental, Social and Governance (ESG), Other Policy Issues, Other Professional Services, Environment, Social Activism, Congress, Yahoo! Finance, Eldridge Industries, International Monetary Fund, Bangladesh Technical Education Board, Milken Institute, Wells Fargo, News, Kroger, American Cancer Society, Partnership, Conference, Fortune 500, African Rainbow Minerals, Council on Foreign Relations, Entrepreneurship, Inter-American Development Bank, CNBC, Representative, Bloomberg, Second Continental Congress, Foreign policy, Guggenheim Partners, American Heart Association, Fox Business, Renewable energy

The 2024 Milken Institute Global Conference opens Sunday, May 5 and will draw more than 4,500 attendees, including global leaders, C-suite executives from Fortune 500 companies, experts and innovators to discuss strategies aimed at shaping a shared future.

Key Points: 
  • The 2024 Milken Institute Global Conference opens Sunday, May 5 and will draw more than 4,500 attendees, including global leaders, C-suite executives from Fortune 500 companies, experts and innovators to discuss strategies aimed at shaping a shared future.
  • In addition to the speakers previously announced , the following national and global leaders have been added to what will be a powerful program during the four-day event.
  • The Milken Institute will livestream Global Conference public sessions, expanding access to the event.
  • Sign up here to stay informed of the latest news on the conference with regular updates published from POLITICO’s special edition of the “Global Playbook” newsletter.

Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

Retrieved on: 
星期三, 五月 1, 2024
FDA, Protein, APC, MRNA, Risk, Moderna, News, Death, Partnership, Skin cancer, Vaccine, ASCO, Spyglass, AACR, NK, Lung cancer, Colorectal cancer, CNBC, NMIBC, Infection, DPX, Messenger, CD8, Merck, NSCLC, RSV, Autumn, Safety, Triangle, Survival, American Cancer Society, DNA, Therapy, Medicine, Melanoma, Pembrolizumab, Biology, Peanut, Cancer, A9, Interview, Immunotherapy, DSM-IV codes, HSV, Habit, Zika virus, COVID-19, Disease, Patent, Patient, Society, Acquisition, Peptide, Antigen, Immune system

VANCOUVER, BC, May 1, 2024 /PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%. According to experts at last year's annual American Society of Clinical Oncology (ASCO) meeting, a little-known bacteria could be behind the rising rates of cancer in people under 40, along with pointing towards bad habits such as highly-processed diets and heavy alcohol use being potential catalysts. While five-year cancer survival rates are on an upward trend, the biotech sector is racing to meet these challenges head on with new treatments and safeguards against cancer, including recent developments from companies such as BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), Moderna, Inc. (NASDAQ: MRNA), Boundless Bio, Inc. (NASDAQ: BOLD), ImmunityBio, Inc. (NASDAQ: IBRX), and MacroGenics, Inc. (NASDAQ: MGNX).

Key Points: 
  • A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%.
  • "We now have massive opportunities in oncology, infectious disease, allergy desensitization, and autoimmune diseases," said Kenneth Kovan, President and Chief Operating Officer of BioVaxys.
  • The joint Moderna/Merck efforts are also testing the vaccine with Keytruda against other tumor types, including non-small cell lung cancer.
  • This shot is designed to train the immune system to recognize and attack specific mutations in cancer cells.

Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

Retrieved on: 
星期三, 五月 1, 2024
FDA, Protein, APC, MRNA, Risk, Moderna, News, Death, Partnership, Skin cancer, Vaccine, ASCO, Spyglass, AACR, NK, Lung cancer, Colorectal cancer, CNBC, NMIBC, Infection, DPX, Messenger, CD8, Merck, NSCLC, RSV, Autumn, Safety, Triangle, Survival, American Cancer Society, DNA, Therapy, Medicine, Melanoma, Pembrolizumab, Biology, Peanut, Cancer, A9, Interview, Immunotherapy, DSM-IV codes, HSV, Habit, Zika virus, COVID-19, Disease, Patent, Patient, Society, Acquisition, Peptide, Antigen, Immune system

VANCOUVER, BC, May 1, 2024 /PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%. According to experts at last year's annual American Society of Clinical Oncology (ASCO) meeting, a little-known bacteria could be behind the rising rates of cancer in people under 40, along with pointing towards bad habits such as highly-processed diets and heavy alcohol use being potential catalysts. While five-year cancer survival rates are on an upward trend, the biotech sector is racing to meet these challenges head on with new treatments and safeguards against cancer, including recent developments from companies such as BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), Moderna, Inc. (NASDAQ: MRNA), Boundless Bio, Inc. (NASDAQ: BOLD), ImmunityBio, Inc. (NASDAQ: IBRX), and MacroGenics, Inc. (NASDAQ: MGNX).

Key Points: 
  • A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%.
  • "We now have massive opportunities in oncology, infectious disease, allergy desensitization, and autoimmune diseases," said Kenneth Kovan, President and Chief Operating Officer of BioVaxys.
  • The joint Moderna/Merck efforts are also testing the vaccine with Keytruda against other tumor types, including non-small cell lung cancer.
  • This shot is designed to train the immune system to recognize and attack specific mutations in cancer cells.

Resource-Appropriate Cancer Care, Including Coexisting Health Issues of HIV and Cancer, to be Addressed During Meeting in Nairobi

Retrieved on: 
星期三, 五月 1, 2024
Cancer, NCCN, AIDS, ACC, Safety, American Cancer Society, Uganda Cancer Institute, HIV/AIDS, ACS, CHAI, Senior, Clinton Foundation, Patient, MPH, Drug, HIV, MBA, Kaposi's sarcoma, Non-Hodgkin lymphoma, Dietary supplement

NAIROBI, Kenya, May 1, 2024 /PRNewswire/ -- Local and global experts are meeting in Nairobi, Kenya to update clinical practice guidelines as part of ongoing work with Allied Against Cancer—a collaboration between the National Comprehensive Cancer Network® (NCCN®), African Cancer Coalition (ACC), American Cancer Society (ACS), and Clinton Health Access Initiative (CHAI). The meeting brings together subject matter experts to update NCCN Harmonized Guidelines™ for Sub-Saharan Africa, featuring updates for treating cancer in people with HIV and other important topics. The event runs from May 1-3, 2024.

Key Points: 
  • The meeting brings together subject matter experts to update NCCN Harmonized Guidelines™ for Sub-Saharan Africa, featuring updates for treating cancer in people with HIV and other important topics.
  • "Many cancers occur more frequently in people with HIV and AIDS, including AIDS-defining cancers like non-Hodgkin lymphoma, Kaposi sarcoma, and invasive cervical cancer.
  • The NCCN Harmonized Guidelines™ employ color-coded recommendations to delineate the best possible cancer care across various settings and resource availability.
  • The Nairobi meeting will focus on updates to the NCCN Harmonized Guidelines™ for People Living with HIV, as well as the following cancer types:

Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI

Retrieved on: 
星期三, 五月 1, 2024
Cytogenetics, Hospital, Prognosis, Research, International, American Cancer Society, MD, Digital, Pathology, Transport, Growth, Quest Diagnostics, Intelligence, Marie Cassidy, Diagnosis, Senior, Patient, Microbiology, Acquisition, Workforce, DGX, Medical imaging

SECAUCUS, N.J. and BOSTON, May 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.

Key Points: 
  • Under the terms of a definitive agreement, Quest will acquire select assets of PathAI Diagnostics, the business of PathAI that provides anatomic and digital pathology laboratory services.
  • At closing, PathAI Diagnostics' state-of-the-art digitized laboratory in Memphis, Tennessee will become Quest's AI and digital R&D and solutions center, supporting Quest's specialty pathology businesses, AmeriPath and Dermpath Diagnostics.
  • Under separate agreements, Quest will license PathAI's AISight™ digital pathology image management system to support its pathology laboratories and customer sites in the United States.
  • "The PathAI Diagnostics laboratory in Memphis will allow Quest to accelerate its digital journey with an already digitized laboratory."